159 related articles for article (PubMed ID: 2434277)
1. Hematologic depression following therapy with strontium-89 chloride.
Cowan RJ; Chilton HM; Cooper MR; Ferree CR; Watson EE; Robinson RG
Clin Nucl Med; 1986 Dec; 11(12):845-6. PubMed ID: 2434277
[TBL] [Abstract][Full Text] [Related]
2. Strontium-89 chloride (Metastron) for palliative treatment of bony metastases. The University of Minnesota experience.
Lee CK; Aeppli DM; Unger J; Boudreau RJ; Levitt SH
Am J Clin Oncol; 1996 Apr; 19(2):102-7. PubMed ID: 8610630
[TBL] [Abstract][Full Text] [Related]
3. Palliation of multiple bone metastases from prostatic carcinoma with strontium-89.
Tennvall J; Darte L; Lundgren R; el Hassan AM
Acta Oncol; 1988; 27(4):365-9. PubMed ID: 2462438
[TBL] [Abstract][Full Text] [Related]
4. Strontium 89 therapy for the palliation of pain due to osseous metastases.
Robinson RG; Preston DF; Schiefelbein M; Baxter KG
JAMA; 1995 Aug; 274(5):420-4. PubMed ID: 7542352
[TBL] [Abstract][Full Text] [Related]
5. [89Sr Therapy for pain relief in patients with bone metastases].
Koizumi K; Arbab AS; Toyama K; Shirasu M; Osawa S; Araki T; Yamaguchi M; Onishi H; Araki T; Arai T; Komatsu H; Ueno A; Nokata H
Kaku Igaku; 1996 Nov; 33(11):1243-8. PubMed ID: 8986064
[TBL] [Abstract][Full Text] [Related]
6. [A strontium-89 injection: a simple treatment of painful bone metastases in patients with prostate cancer unresponsive to hormonal treatment].
Jager PL; Mensink HJ; van den Bergh AC; Piers DA
Ned Tijdschr Geneeskd; 1999 May; 143(19):969-73. PubMed ID: 10368715
[TBL] [Abstract][Full Text] [Related]
7. Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group.
Brundage MD; Crook JM; Lukka H
Cancer Prev Control; 1998 Apr; 2(2):79-87. PubMed ID: 9765768
[TBL] [Abstract][Full Text] [Related]
8. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy.
Tu SM; Kim J; Pagliaro LC; Vakar-Lopez F; Wong FC; Wen S; General R; Podoloff DA; Lin SH; Logothetis CJ
J Clin Oncol; 2005 Nov; 23(31):7904-10. PubMed ID: 16258090
[TBL] [Abstract][Full Text] [Related]
9. Strontium-89 (Metastron) versus external beam radiotherapy in patients with painful bone metastases secondary to prostatic cancer: preliminary report of a multicenter trial. UK Metastron Investigators Group.
Bolger JJ; Dearnaley DP; Kirk D; Lewington VJ; Mason MD; Quilty PM; Reed NS; Russell JM; Yardley J
Semin Oncol; 1993 Jun; 20(3 Suppl 2):32-3. PubMed ID: 7684863
[No Abstract] [Full Text] [Related]
10. Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma.
Buchali K; Correns HJ; Schuerer M; Schnorr D; Lips H; Sydow K
Eur J Nucl Med; 1988; 14(7-8):349-51. PubMed ID: 2460352
[TBL] [Abstract][Full Text] [Related]
11. Strontium chloride Sr 89 for treating pain from metastatic bone disease.
Nightengale B; Brune M; Blizzard SP; Ashley-Johnson M; Slan S
Am J Health Syst Pharm; 1995 Oct; 52(20):2189-95. PubMed ID: 8564588
[TBL] [Abstract][Full Text] [Related]
12. Palliation of bone pain in patients with metastatic cancer using strontium-89 (Metastron).
Kan MK
Cancer Nurs; 1995 Aug; 18(4):286-91. PubMed ID: 7545083
[TBL] [Abstract][Full Text] [Related]
13. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy.
Laing AH; Ackery DM; Bayly RJ; Buchanan RB; Lewington VJ; McEwan AJ; Macleod PM; Zivanovic MA
Br J Radiol; 1991 Sep; 64(765):816-22. PubMed ID: 1717094
[TBL] [Abstract][Full Text] [Related]
14. Disseminated intravascular coagulation in a patient treated with strontium-89 for metastatic carcinoma of the prostate.
Paszkowski AL; Hewitt DJ; Taylor A
Clin Nucl Med; 1999 Nov; 24(11):852-4. PubMed ID: 10551466
[TBL] [Abstract][Full Text] [Related]
15. Strontium-89 therapy for painful osseous metastatic prostate and breast cancer.
Hansen DV; Holmes ER; Catton G; Thorne DA; Chadwick DH; Schmutz DA
Am Fam Physician; 1993 Jun; 47(8):1795-800. PubMed ID: 7684554
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of symptomatic bone metastases of prostatic carcinoma using strontium chloride (Sr-89)].
Dormia E; Mantovani F; Minervini S; Malagola G; Castellani R; Dormia G; Gonnella G; Mazza L; Luongo P; Bertana F
Arch Ital Urol Androl; 1993 Apr; 65(2):161-6. PubMed ID: 8330061
[TBL] [Abstract][Full Text] [Related]
17. Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma.
Papatheofanis FJ
J Nucl Med; 1997 Aug; 38(8):1175-9. PubMed ID: 9255144
[TBL] [Abstract][Full Text] [Related]
18. [Strontium-89 for bone metastases from prostate cancer: an update].
Zhao WW; Xie P; Deng HF
Zhonghua Nan Ke Xue; 2010 Mar; 16(3):269-72. PubMed ID: 20369560
[TBL] [Abstract][Full Text] [Related]
19. [89-Strontium for painful osteoblastic metastases].
Golan H; Ratz D
Harefuah; 1995 May; 128(10):650-4. PubMed ID: 7541384
[No Abstract] [Full Text] [Related]
20. Strontium and samarium therapy for bone metastases from prostate carcinoma.
Dickie GJ; Macfarlane D
Australas Radiol; 1999 Nov; 43(4):476-9. PubMed ID: 10901963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
